Modulating growth factor signaling through precise and novel treatments
Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
AGOMAB REPORTS POSITIVE PHASE 1 RESULTS WITH AGMB-129, A GI-RESTRICTED ALK5 INHIBITOR FOR FIBROSTENOSING CROHN’S DISEASE
February 2nd 2023
Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
Agomab Therapeutics Selected as One of Fierce Biotech's ``Fierce 15`` Companies of 2022
“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
Tim Knotnerus, Chief Executive Officer